Watson Biotechnology: Amendment of Exclusive Re-License Agreement for Microbial Health Targeting Technology Expands Collaboration to Non-Patient Areas

Watson Biological announced that the board of directors will convene on July 30, 2025 to review and approve the signing of amendments to expand the research and commercial applications of "core microbiome therapy" in the fields of precision microbiome health and functional nutrition intervention. The amendments primarily include broadening the scope of collaboration to non-patient areas, granting the company exclusive rights to develop, manufacture, and commercialize products targeting non-patient populations in mainland China, Hong Kong, and Macau, and revising financial terms, deadlines, and due diligence clauses in the agreement. This signing will not have a significant impact on the company's performance for the current year and will help ensure efficient use of funds.